These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 23963056)

  • 1. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
    Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
    J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders.
    Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gasso P; Deulofeu R; Mane A; Catalan R; Carne X
    Psychiatry Res; 2008 Nov; 161(2):131-41. PubMed ID: 18922583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study.
    Sáiz PA; García-Portilla MP; Arango C; Morales B; Arias B; Corcoran P; Fernández JM; Alvarez V; Coto E; Bascarán MT; Bousoño M; Fañanas L; Bobes J
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):26-31. PubMed ID: 19766158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.
    Güzey C; Scordo MG; Spina E; Landsem VM; Spigset O
    Eur J Clin Pharmacol; 2007 Mar; 63(3):233-41. PubMed ID: 17225991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders.
    Vallelunga A; Flaibani R; Formento-Dojot P; Biundo R; Facchini S; Antonini A
    Parkinsonism Relat Disord; 2012 May; 18(4):397-9. PubMed ID: 22113132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics.
    Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gassó P; Catalan R; Mateos JJ; Lomeña F; Parellada E
    Schizophr Res; 2007 Feb; 90(1-3):115-22. PubMed ID: 17150335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Family-based and case-control study of DRD2, DAT, 5HTT, COMT genes polymorphisms in alcohol dependence.
    Samochowiec J; Kucharska-Mazur J; Grzywacz A; Jabłoński M; Rommelspacher H; Samochowiec A; Sznabowicz M; Horodnicki J; Sagan L; Pełka-Wysiecka J
    Neurosci Lett; 2006 Dec; 410(1):1-5. PubMed ID: 17079080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of DAT1 and COMT differentially associate with actigraphy-derived sleep-wake cycles in young adults.
    Valomon A; Holst SC; Bachmann V; Viola AU; Schmidt C; Zürcher J; Berger W; Cajochen C; Landolt HP
    Chronobiol Int; 2014 Jun; 31(5):705-14. PubMed ID: 24625311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of dopamine polymorphisms on the risk for anorexia nervosa and associated psychopathological features.
    Gervasini G; Gordillo I; García-Herráiz A; Flores I; Jiménez M; Monge M; Carrillo JA
    J Clin Psychopharmacol; 2013 Aug; 33(4):551-5. PubMed ID: 23775054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
    Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
    Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced dopamine receptor sensitivity as an intermediate phenotype in alcohol dependence and the role of the COMT Val158Met and DRD2 Taq1A genotypes.
    Schellekens AF; Franke B; Ellenbroek B; Cools A; de Jong CA; Buitelaar JK; Verkes RJ
    Arch Gen Psychiatry; 2012 Apr; 69(4):339-48. PubMed ID: 22474103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.
    Tybura P; Trześniowska-Drukała B; Bienkowski P; Beszlej A; Frydecka D; Mierzejewski P; Samochowiec A; Grzywacz A; Samochowiec J
    Psychiatry Res; 2014 Oct; 219(2):261-7. PubMed ID: 24930580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association study of the SLC6A3 VNTR (DAT) and DRD2/ANKK1 Taq1A polymorphisms with alcohol dependence in a population from northeastern Brazil.
    Vasconcelos AC; Neto Ede S; Pinto GR; Yoshioka FK; Motta FJ; Vasconcelos DF; Canalle R
    Alcohol Clin Exp Res; 2015 Feb; 39(2):205-11. PubMed ID: 25684044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMT Val158Met modulates the effect of childhood adverse experiences on the risk of alcohol dependence.
    Schellekens AF; Franke B; Ellenbroek B; Cools A; de Jong CA; Buitelaar JK; Verkes RJ
    Addict Biol; 2013 Mar; 18(2):344-56. PubMed ID: 22509987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential associations of dopamine-related polymorphisms with discrete components of reaction time variability: relevance for attention deficit/hyperactivity disorder.
    Grant P; Kuepper Y; Wielpuetz C; Hennig J
    Neuropsychobiology; 2014; 69(4):220-6. PubMed ID: 24942140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
    Gunes A; Scordo MG; Jaanson P; Dahl ML
    Psychopharmacology (Berl); 2007 Mar; 190(4):479-84. PubMed ID: 17102980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia--relationship with COMT Val¹⁰⁸/¹⁵⁸Met polymorphism, gender and symptomatology.
    Boot E; Booij J; Abeling N; Meijer J; da Silva Alves F; Zinkstok J; Baas F; Linszen D; van Amelsvoort T
    J Psychopharmacol; 2011 Jul; 25(7):888-95. PubMed ID: 21447540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes.
    Gassó P; Mas S; Crescenti A; Alvarez S; Parramon G; Garcia-Rizo C; Parellada E; Bernardo M; Lafuente A
    Psychiatry Res; 2010 Jan; 175(1-2):173-5. PubMed ID: 19892410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia.
    Matsumoto C; Shinkai T; Hori H; Ohmori O; Nakamura J
    Psychiatry Res; 2004 Jun; 127(1-2):1-7. PubMed ID: 15261699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms.
    Gupta M; Chauhan C; Bhatnagar P; Gupta S; Grover S; Singh PK; Purushottam M; Mukherjee O; Jain S; Brahmachari SK; Kukreti R
    Pharmacogenomics; 2009 Feb; 10(2):277-91. PubMed ID: 19207030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.